Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A, Clotet B, Staszewski S, van Eeden A, Clumeck N, Moroni M, Pavia AT, Schmidt RE, Gonzalez-Lahoz J, Montaner J, Antunes F, Gulick R, Bánhegyi D, van der Valk M, Reiss P, van Weert L, van Leth F, Johnson VA, Sommadossi JP, Lange JM. van Leeuwen R, et al. Among authors: staszewski s. AIDS. 2003 May 2;17(7):987-99. doi: 10.1097/00002030-200305020-00007. AIDS. 2003. PMID: 12700448 Clinical Trial.
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.
May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M; Antiretroviral Therapy (ART) Cohort Collaboration. May M, et al. Among authors: staszewski s. AIDS. 2007 May 31;21(9):1185-97. doi: 10.1097/QAD.0b013e328133f285. AIDS. 2007. PMID: 17502729 Free PMC article.
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S; QUEST Study Group. Hoen B, et al. Among authors: staszewski s. Clin Infect Dis. 2007 Aug 1;45(3):381-90. doi: 10.1086/519428. Epub 2007 Jun 26. Clin Infect Dis. 2007. PMID: 17599319 Free article.
Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.
Combadière B, Vogt A, Mahé B, Costagliola D, Hadam S, Bonduelle O, Sterry W, Staszewski S, Schaefer H, van der Werf S, Katlama C, Autran B, Blume-Peytavi U. Combadière B, et al. Among authors: staszewski s. PLoS One. 2010 May 26;5(5):e10818. doi: 10.1371/journal.pone.0010818. PLoS One. 2010. PMID: 20520820 Free PMC article. Clinical Trial.
2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.
Revell AD, Wang D, Perez-Elias MJ, Wood R, Cogill D, Tempelman H, Hamers RL, Reiss P, van Sighem A, Rehm CA, Agan B, Alvarez-Uria G, Montaner JSG, Lane HC, Larder BA; RDI study group. Revell AD, et al. J Antimicrob Chemother. 2021 Jun 18;76(7):1898-1906. doi: 10.1093/jac/dkab078. J Antimicrob Chemother. 2021. PMID: 33792714 Free PMC article.
Ethical, Legal, and Religious Aspects at the Border of Viability.
Oehmke F, Lauer T, Baecker J, Mader S, Soydan N, Born T, Brumhard M, Dettmeyer R, Staszewski S, Heinemann T, Kilian U, Sarikaya Y, Kress H, Tinneberg HR, Bilgin Y, Zimmer KP, Ehrhardt H. Oehmke F, et al. Among authors: staszewski s. Front Pediatr. 2019 May 8;7:175. doi: 10.3389/fped.2019.00175. eCollection 2019. Front Pediatr. 2019. PMID: 31139602 Free PMC article. No abstract available.
2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings.
Revell AD, Wang D, Perez-Elias MJ, Wood R, Cogill D, Tempelman H, Hamers RL, Reiss P, van Sighem AI, Rehm CA, Pozniak A, Montaner JSG, Lane HC, Larder BA; RDI Data and Study Group. Revell AD, et al. J Antimicrob Chemother. 2018 Aug 1;73(8):2186-2196. doi: 10.1093/jac/dky179. J Antimicrob Chemother. 2018. PMID: 29889249 Free PMC article.
An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype.
Revell AD, Wang D, Wood R, Morrow C, Tempelman H, Hamers RL, Reiss P, van Sighem AI, Nelson M, Montaner JS, Lane HC, Larder BA; RDI Data and Study Group. Revell AD, et al. J Antimicrob Chemother. 2016 Oct;71(10):2928-37. doi: 10.1093/jac/dkw217. Epub 2016 Jun 20. J Antimicrob Chemother. 2016. PMID: 27330070 Free PMC article.
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.
Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Mocroft A, et al. PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar. PLoS Med. 2015. PMID: 25826420 Free PMC article.
251 results